Drugs / mRNA-0523-L001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06141369 | Jan 2024 → Dec 2026 expected | adrenal cortex carcinoma, medullary thyroid gland carcinoma, pancreatic neuroendocrine tumor, thymic neuroendocrine carcinoma | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-0523-L001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06141369 ↗ |
| Modality | Messenger RNA (mRNA) | “Individualized mRNA neoantigen vaccine (mRNA-0523-L001)” NCT06141369 ↗ |
| Route | Intramuscular | “injected intramuscularly” NCT06141369 ↗ |